Welcome to our dedicated page for Sharps Tech SEC filings (Ticker: STSS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Curious how Sharps Technology’s smart-safety syringe strategy shows up in SEC paperwork? Investors opening a Sharps Technology quarterly earnings report 10-Q filing often want details on Hungary plant capacity, cash burn, and new supply contracts. Others search for a Sharps Technology annual report 10-K simplified view of patent litigation risks or for a Sharps Technology proxy statement executive compensation breakdown of management incentives tied to syringe volumes.
Scroll down and you’ll find every document—10-K, 10-Q, 8-K, S-1—as soon as EDGAR releases them. Stock Titan’s AI immediately delivers plain-English summaries so you can start understanding Sharps Technology SEC documents with AI instead of parsing medical-device jargon. Need to act fast on Sharps Technology Form 4 insider transactions real-time? Our alerts flag executive stock movements the moment they post, letting you monitor Sharps Technology executive stock transactions Form 4 alongside market data.
Use the page to:
- Review 8-K material events explained—plant expansions, distribution deals, or safety-testing updates.
- Compare R&D spending trends with revenue guidance through side-by-side filing analysis.
- Track Sharps Technology insider trading Form 4 transactions before option grant dates.
Whether you’re performing a Sharps Technology earnings report filing analysis or scanning a single risk-factor footnote, our AI-powered summaries, keyword jump-to links, and real-time updates save hours. Every Sharps filing is presented clearly, so you can focus on valuing its ultra-low-waste syringe opportunity—not on deciphering dense text.
Sharps Technology (STSS) filed its Q3 2025 10‑Q, highlighting a major shift to a digital‑asset treasury anchored in Solana (SOL). As of September 30, total assets were $443.96M, including SOL at fair value of $404.20M and USDC of $14.70M. Cash was $10.52M. Management states current liquidity is sufficient for the next twelve months and no longer raises substantial doubt about going concern.
Operations reflected the pivot: product revenue was $83,622, and staking revenue was $2,205,423. The quarter included significant operating costs, including selling, general and administrative expenses of $110.72M and a $7.50M impairment of fixed assets tied to the exit from manufacturing, resulting in a net loss of $105.33M. A 10% change in SOL prices would have impacted income by about $40.4M for the period, underscoring market sensitivity.
Financing activity was robust, with $210.73M of net cash provided year‑to‑date. The company received $144.04M of digital assets and $86.10M of USDC from common stock issuances. Shares outstanding were 27,626,498 at quarter‑end and 28,226,153 as of November 14, 2025. Sharps now reports two segments: Medical Device Packaging Products and Digital Assets.
Sharps Technology, Inc. (Nasdaq: STSS)
The company is not selling shares and will not receive proceeds from Selling Stockholder sales. It could receive up to $614,837,807.75 in gross proceeds if all warrants are exercised. Shares outstanding were 28,226,153 as of October 17, 2025. The company highlights extensive risk factors tied to its SOL-focused digital asset treasury strategy, staking operations, market volatility, custody, DeFi usage, and evolving regulation.
Sharps Technology (STSS) reported results of its special meeting of stockholders. Of 26,600,848 shares eligible to vote as of September 16, 2025, 17,779,090 shares were present or represented by proxy, establishing a 66.9% quorum.
Stockholders elected Annemarie Tierney as director with 17,770,289 votes for and 8,801 withheld. Proposal 2 was approved with 17,750,927 votes for, 27,713 against, and 450 abstentions. Proposal 3 was approved with 17,743,259 votes for, 35,546 against, and 285 abstentions. Proposal 4 was approved with 16,802,916 votes for, 51,835 against, and 924,339 abstentions.
Reporting person Zhang Yuwen, Chief Investment Officer and director of Sharps Technology Inc. (STSS), reported a grant of stock options on
Sharps Technology Inc. (STSS) director and Chief Investment Officer Yuwen Zhang filed an initial Form 3 reporting indirect beneficial ownership of 14,040 shares of common stock that are held indirectly through a spouse. The event date listed is
Sharps Technology, Inc. filed a Definitive Proxy Statement asking shareholders to vote on four proposals at a special meeting, principally the approval to issue up to 49,673,120 shares of common stock upon exercise of outstanding Cryptocurrency Warrants and a separate approval for issuance upon exercise of Strategic Advisor Warrants. The filing lists board nominees and executive officers, including Paul K. Danner as Executive Chairman and Principal Executive Officer and Andrew R. Crescenzo as CFO. The statement notes the threshold rule that an issuance equaling or exceeding 20% of outstanding common stock requires shareholder approval. Specific beneficial ownership lines are summarized with individual directors and officers holding less than 1% each.
FAQ
What is the current stock price of Sharps Tech (STSS)?
What is the market cap of Sharps Tech (STSS)?
